LDLR and non-small cell lung carcinoma: Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel <i>LDLR-ROS1</i> Fusion.